<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="T2" position="float">
 <label>Table 2</label>
 <caption>
  <p>Posted clinical trials evaluating Dengue vaccine candidates in a prime-boost regime.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th valign="top" align="left" rowspan="1" colspan="1">
     <bold>Vaccine candidate</bold>
    </th>
    <th valign="top" align="left" rowspan="1" colspan="1">
     <bold>Status and study's purposes</bold>
    </th>
    <th valign="top" align="left" rowspan="1" colspan="1">
     <bold>
      <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/" xmlns:xlink="http://www.w3.org/1999/xlink">Clinical trials.gov</ext-link> identifier
     </bold>
    </th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Sponsor:</bold> National Institute of Allergy and Infectious Diseases (NIAID)
    </td>
    <td valign="top" align="left" rowspan="6" colspan="1">
     <bold>Phase 1:</bold> The purpose of this study is to determine the safety and immune response to a vaccine containing a particular dengue serotype when an individual has been previously vaccinated with a different dengue serotype
    </td>
    <td valign="top" align="left" rowspan="6" colspan="1">NCT00458120 
     <break/>(
     <xref rid="B76" ref-type="bibr">76</xref>)
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>               Prime ---------------   boost</bold>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">            rDEN1Δ30 --- rDEN2/4Δ30(ME) (10
     <sup>3</sup> PFU)
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">            rDEN2/4Δ30(ME) --- rDEN1Δ30 (10
     <sup>3</sup> PFU)
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">            rDEN4Δ30------------rDEN1Δ30 (10
     <sup>3</sup> PFU)
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">            rDEN4Δ30 --- rDEN2/4Δ30(ME)(10
     <sup>3</sup> PFU)
    </td>
   </tr>
   <tr style="border-top: thin solid #000000;">
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Sponsor:</bold> National Institute of Allergy and Infectious Diseases (NIAID)
    </td>
    <td valign="top" align="left" rowspan="3" colspan="1">
     <bold>Phase 1:</bold> The purpose of this study is to evaluate the immunologic and clinical response to two dengue vaccines (rDEN1Δ30 and rDEN2Δ30-7169), given 9 months apart, in healthy adults with no history of previous flavivirus infection
    </td>
    <td valign="top" align="left" rowspan="3" colspan="1">NCT02392325</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>               Prime ---------------   boost</bold>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">            rDEN1Δ30 --------- rDEN2Δ30-7169 (10
     <sup>3</sup> PFU)
    </td>
   </tr>
   <tr style="border-top: thin solid #000000;">
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Sponsor:</bold> National Institute of Allergy and Infectious Diseases (NIAID)
    </td>
    <td valign="top" align="left" rowspan="3" colspan="1">
     <bold>Phase 1:</bold> The purpose of this study is to evaluate the potential synergistic effect of administering 2 dengue vaccine candidates that were previously shown to be safe and immunogenic in humans. A prime-boost study of tetravalent dengue virus
    </td>
    <td valign="top" align="left" rowspan="3" colspan="1">NCT02239614</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>               Prime ---------------   boost</bold>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">            TDENV-PIV (alum) ---180 days-- (TDENV-LAV) (F17)</td>
   </tr>
   <tr style="border-top: thin solid #000000;">
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Sponsor:</bold> U.S. Army Medical Research and Materiel Command
    </td>
    <td valign="top" align="left" rowspan="4" colspan="1">
     <bold>Phase 1:</bold> This is a study of the prime-boost vaccine candidates given in the prime-boost regimen previously demonstrated to have a high level of immunogenicity and immune durability: Day 0 prime (PIV) and Day 180 boost (LAV), and compare it with a previously untested schedule: Day 0 prime (PIV) and Day 90 boost (LAV)
    </td>
    <td valign="top" align="left" rowspan="4" colspan="1">NCT03141138</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>               Prime ---------------   boost</bold>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">            TDENV-PIV (alum) ---180 days-- (TDENV-LAV) (F17)</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">            TDENV-PIV (alum) ---90 days--- (TDENV-LAV) (F17)</td>
   </tr>
   <tr style="border-top: thin solid #000000;">
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Sponsor:</bold> U.S. Army Medical Research and Materiel Command
    </td>
    <td valign="top" align="left" rowspan="5" colspan="1">
     <bold>Phase 1:</bold> This study is being done to evaluate the safety and immune reaction of administering one dose of dengue purified inactivated vaccine and one dose of dengue live attenuated vaccine compared to two doses of inactivated vaccine
    </td>
    <td valign="top" align="left" rowspan="5" colspan="1">NCT03110952</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>               Prime ---------------    boost</bold>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">            TDENV-PIV (AS03B) ----- TDENV-PIV (AS03B)</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">            TDENV-F17 ---------------TDENV-PIV (AS03B)</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">            TDENV-PIV (AS03B) ------------------ TDENV-F17</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
